Automated High-purity Exosome isolation-based AD diagnostics system (AHEADx)

基于自动化高纯度外泌体分离的 AD 诊断系统 (AHEADx)

基本信息

  • 批准号:
    10738697
  • 负责人:
  • 金额:
    $ 78.88万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-09-01 至 2028-05-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Alzheimer’s disease (AD) is a severe neurodegenerative illness that destroys cognitive abilities causing memory impairment, difficulties with speech and language, behavioral changes, functional decline, and significant impairment. AD affects an estimated 13.8 million people in the United States and 50 million worldwide, imposing a significant economic burden and global health crisis. While many researchers are working towards developing a cure for the disease, there is currently no objective, point-of-care diagnostic test for the early diagnosis of AD, significantly limiting screening efforts for clinical studies and delaying treatment for patients suffering from early AD pathology. The current standard methods for AD diagnosis involve expensive PET imaging methods that irradiate the patient and cerebrospinal fluid biomarker tests, which are invasive and require a lumbar puncture. Recently, exosomes (30-150 nm extracellular vesicles) have been identified as a possible tool for AD diagnosis, attributed to their ubiquitous presence in biofluids, their ability to pass through the blood-brain-barrier, and their rich library of AD-relevant physiological information present in the molecular cargo they carry, making them prime candidates for use as biomarkers. However, the clinical application of exosomes is hindered by slow, inefficient techniques for exosome isolation and the absence of standardized exosomal biomarker detection and analysis. Thus, an automated, highly sensitive, fast, and efficient system that can isolate exosomes from biofluids and analyze the miRNAs and proteins they contain will significantly improve early-stage AD diagnosis efforts. In this R01 project, we will develop an Automated High-purity Exosome isolation-based AD diagnostics system (AHEADx) to address the limitations of current technologies. The proposed AHEADx platform includes two units: (1) a rapid (<1 min), high-yield (>90%), and high-purity (>90%) acoustic Bessel beam-based separation unit to isolate and enrich exosomes from whole blood, and (2) a rapid (<6 mins), highly sensitive photonic PCR and immuno-PCR (~1 copy/µL for nucleic acids and ~5 copies/µL for proteins, respectively) utilizing a plasmonic nanopillar array to enable on-chip thermocycling and multiplexed exosomal screening of combined panels of AD-relevant biomarkers. Our rapid and precise AHEADx platform will provide a simple, minimally invasive liquid biopsy to detect molecular AD biomarkers with ultrahigh accuracy and sensitivity in early-stage AD patients, allowing for an effective diagnostic method of AD screening for earlier treatment before the onset of severe symptoms of the disease and enable long-term studies on AD development and progression. Additionally, the proposed technology will accelerate the discovery of new exosomal miRNA and protein AD biomarkers and help to elucidate the mechanisms in which exosome trafficking and transport contribute to AD pathology. With these advantages, our AHEADx platform can potentially exceed current clinical standards in AD diagnostics, addressing a significant need in the field and providing a compelling platform for earlier, accurate, and sensitive detection of AD and long-term studies on the effects of novel AD therapeutics.
项目总结 阿尔茨海默病(AD)是一种严重的神经退行性疾病,会破坏导致记忆的认知能力 功能障碍、言语和语言障碍、行为改变、功能衰退和显著 减损。据估计,美国有1380万人受到广告的影响,全球有5000万人受到广告的影响。 严重的经济负担和全球健康危机。当许多研究人员正在努力开发 作为一种治愈疾病的方法,目前还没有客观的、临床点诊断测试来早期诊断阿尔茨海默病, 大大限制了临床研究的筛查工作,并推迟了对早期糖尿病患者的治疗 公元病理学。目前诊断AD的标准方法包括昂贵的PET成像方法, 照射患者和脑脊液生物标记物测试,这是侵入性的,需要腰椎穿刺术。 最近,Exosome(30-150 nm细胞外小泡)已被确定为一种可能的AD诊断工具。 归因于它们在生物体液中的普遍存在,它们通过血脑屏障的能力,以及它们的 丰富的AD相关生理信息库存在于它们携带的分子货物中,使它们成为主要的 作为生物标志物的候选者。然而,外切体的临床应用受到了缓慢、低效的阻碍。 外切体分离技术和缺乏标准化的外切体生物标志物检测和分析。 因此,一种自动化、高度敏感、快速和高效的系统可以从生物体液中分离外切体和 分析它们所包含的miRNAs和蛋白质将显著改善早期AD诊断工作。在这 在R01项目的基础上,我们将开发一个基于自动化高纯度Exosome分离的AD诊断系统 (AHEADx)以解决当前技术的限制。拟议的AHEADx平台包括两个单元: (1)快速(&lt;1分钟)、高产量(&gt;90%)和高纯度(&gt;90%)的基于声学贝塞尔波束的分离单元 从全血中分离和浓缩外切体,以及(2)快速(&lt;6分钟)、高灵敏的光子聚合酶链式反应和 血浆免疫聚合酶链式反应(核酸~1拷贝/微米L,蛋白质~5拷贝/微米L) 纳米管阵列可实现芯片上热循环和多路外体筛选的组合面板 与广告相关的生物标志物。我们快速而精确的AHEADx平台将提供简单、微创的液体 以超高准确度和灵敏度检测早期AD患者的分子AD生物标志物的活检 为重症发作前的早期治疗提供了一种有效的AD筛查诊断方法 这将有助于对阿尔茨海默病的症状进行研究,并对阿尔茨海默病的发展和进展进行长期研究。此外, 拟议的技术将加速发现新的外体miRNA和蛋白质AD生物标记物,并有助于 阐明外切体运输和运输在AD病理中的作用机制。有了这些 优势,我们的AHEADx平台在AD诊断方面可能会超过当前的临床标准, 满足现场的重大需求,并为更早、更准确、更敏感地提供一个引人注目的平台 阿尔茨海默病的检测和新的阿尔茨海默病治疗方法的长期研究。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Tony Jun Huang其他文献

Tony Jun Huang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Tony Jun Huang', 18)}}的其他基金

Acoustofluidic Separation of Placental Nanovesicle Subpopulations in Obstetrical Diseases
产科疾病胎盘纳米囊泡亚群的声流分离
  • 批准号:
    10625490
  • 财政年份:
    2021
  • 资助金额:
    $ 78.88万
  • 项目类别:
Development of a digital acoustofluidic system for automating liquid handling in biomedical research
开发用于生物医学研究中液体处理自动化的数字声流系统
  • 批准号:
    10405571
  • 财政年份:
    2021
  • 资助金额:
    $ 78.88万
  • 项目类别:
Development of a digital acoustofluidic system for automating liquid handling in biomedical research
开发用于生物医学研究中液体处理自动化的数字声流系统
  • 批准号:
    10175836
  • 财政年份:
    2021
  • 资助金额:
    $ 78.88万
  • 项目类别:
Development of a digital acoustofluidic system for automating liquid handling in biomedical research
开发用于生物医学研究中液体处理自动化的数字声流系统
  • 批准号:
    10689706
  • 财政年份:
    2021
  • 资助金额:
    $ 78.88万
  • 项目类别:
Development of a digital acoustofluidic system for automating liquid handling in biomedical research
开发用于生物医学研究中液体处理自动化的数字声流系统
  • 批准号:
    10795366
  • 财政年份:
    2021
  • 资助金额:
    $ 78.88万
  • 项目类别:
Acoustofluidic Separation of Placental Nanovesicle Subpopulations in Obstetrical Diseases
产科疾病胎盘纳米囊泡亚群的声流分离
  • 批准号:
    10418609
  • 财政年份:
    2021
  • 资助金额:
    $ 78.88万
  • 项目类别:
AFS/SERS Saliva-based SARS-CoV-2 Earliest Infection and Antibodies Detection
AFS/SERS 基于唾液的 SARS-CoV-2 最早感染和抗体检测
  • 批准号:
    10320991
  • 财政年份:
    2020
  • 资助金额:
    $ 78.88万
  • 项目类别:
AFS/SERS Saliva-based SARS-CoV-2 Earliest Infection and Antibodies Detection
AFS/SERS 基于唾液的 SARS-CoV-2 最早感染和抗体检测
  • 批准号:
    10266399
  • 财政年份:
    2020
  • 资助金额:
    $ 78.88万
  • 项目类别:
Enabling Efficient, Fast, Biocompatible Exosome Separation via Acoustofluidics
通过声流控技术实现高效、快速、生物相容性的外泌体分离
  • 批准号:
    10171868
  • 财政年份:
    2019
  • 资助金额:
    $ 78.88万
  • 项目类别:
Enabling Efficient, Fast, Biocompatible Exosome Separation via Acoustofluidics
通过声流控技术实现高效、快速、生物相容性的外泌体分离
  • 批准号:
    10456734
  • 财政年份:
    2019
  • 资助金额:
    $ 78.88万
  • 项目类别:

相似海外基金

Nonlinear Acoustics for the conditioning monitoring of Aerospace structures (NACMAS)
用于航空航天结构调节监测的非线性声学 (NACMAS)
  • 批准号:
    10078324
  • 财政年份:
    2023
  • 资助金额:
    $ 78.88万
  • 项目类别:
    BEIS-Funded Programmes
ORCC: Marine predator and prey response to climate change: Synthesis of Acoustics, Physiology, Prey, and Habitat In a Rapidly changing Environment (SAPPHIRE)
ORCC:海洋捕食者和猎物对气候变化的反应:快速变化环境中声学、生理学、猎物和栖息地的综合(蓝宝石)
  • 批准号:
    2308300
  • 财政年份:
    2023
  • 资助金额:
    $ 78.88万
  • 项目类别:
    Continuing Grant
University of Salford (The) and KP Acoustics Group Limited KTP 22_23 R1
索尔福德大学 (The) 和 KP Acoustics Group Limited KTP 22_23 R1
  • 批准号:
    10033989
  • 财政年份:
    2023
  • 资助金额:
    $ 78.88万
  • 项目类别:
    Knowledge Transfer Partnership
User-controllable and Physics-informed Neural Acoustics Fields for Multichannel Audio Rendering and Analysis in Mixed Reality Application
用于混合现实应用中多通道音频渲染和分析的用户可控且基于物理的神经声学场
  • 批准号:
    23K16913
  • 财政年份:
    2023
  • 资助金额:
    $ 78.88万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Combined radiation acoustics and ultrasound imaging for real-time guidance in radiotherapy
结合辐射声学和超声成像,用于放射治疗的实时指导
  • 批准号:
    10582051
  • 财政年份:
    2023
  • 资助金额:
    $ 78.88万
  • 项目类别:
Comprehensive assessment of speech physiology and acoustics in Parkinson's disease progression
帕金森病进展中言语生理学和声学的综合评估
  • 批准号:
    10602958
  • 财政年份:
    2023
  • 资助金额:
    $ 78.88万
  • 项目类别:
The acoustics of climate change - long-term observations in the arctic oceans
气候变化的声学——北冰洋的长期观测
  • 批准号:
    2889921
  • 财政年份:
    2023
  • 资助金额:
    $ 78.88万
  • 项目类别:
    Studentship
Collaborative Research: Estimating Articulatory Constriction Place and Timing from Speech Acoustics
合作研究:从语音声学估计发音收缩位置和时间
  • 批准号:
    2343847
  • 财政年份:
    2023
  • 资助金额:
    $ 78.88万
  • 项目类别:
    Standard Grant
Flow Physics and Vortex-Induced Acoustics in Bio-Inspired Collective Locomotion
仿生集体运动中的流动物理学和涡激声学
  • 批准号:
    DGECR-2022-00019
  • 财政年份:
    2022
  • 资助金额:
    $ 78.88万
  • 项目类别:
    Discovery Launch Supplement
Collaborative Research: Estimating Articulatory Constriction Place and Timing from Speech Acoustics
合作研究:从语音声学估计发音收缩位置和时间
  • 批准号:
    2141275
  • 财政年份:
    2022
  • 资助金额:
    $ 78.88万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了